CHRISTOPHER JOHN KENNEY - 12 Mar 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Medical Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
12 Mar 2025
Net transactions value
$0
Form type
4
Filing time
13 Mar 2025, 19:31:01 UTC
Previous filing
12 Mar 2024
Next filing
09 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 12 Mar 2025 Common Shares 80,000 $35.48 Direct F1
transaction XENE Restricted Share Units Award $0 +15,000 $0.000000 15,000 12 Mar 2025 Common Shares 15,000 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.